Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS
Open Access
- 28 September 2006
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 135 (3) , 355-357
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndromeBlood, 2005
- Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)Leukemia, 2005
- The Nonsteroidal Anti-Inflammatory Drug Exisulind Selectively Induces Apoptosis via JNK in Secondary Acute Myeloid Leukemia after Myelodysplastic SyndromeCell Cycle, 2005
- NF-κB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survivalProceedings of the National Academy of Sciences, 2004
- Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromesLeukemia, 2003
- Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDSBlood, 2001
- Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancerJournal of Clinical Investigation, 2001
- Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesisBritish Journal of Haematology, 2000
- Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatmentLeukemia Research, 1998
- Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLCJournal of Pharmaceutical and Biomedical Analysis, 1995